Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute

Status Completed

Clinical Trial Summary

This study will investigate the effect of peripheral acting opioid antagonist (PAMORA) on the disease course of patients with acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating hospitalized patients with acute pancreatitis with a PAMORA (methylnaltrexone).

Clinical Trial Description

In this study, the effects of peripheral acting µ-opioid receptor antagonists (PAMORA) on disease development and progression in patients with acute pancreatitis (AP) will be investigated. Patients with AP will be administered Methylnaltrexone (Relistor®) intravenously. This medication is defined as the investigational product. Relistor® is approved and sold on the Danish marked for treatment of opioid-induced constipation. This PAMORA have not previously been investigated in patients with pancreatitis. The dose regimes for this study will be according to label. It has previously been shown, in patients with opioid-induced obstipation and healthy subjects, that opioid antagonism incl. PAMORA treatment increases gut motility, relaxes gastrointestinal sphincters, increases the intestinal water content and improves the immune response, without affecting analgesia. The affinity of PAMORAs to the µ-opioid receptors is much stronger than opioid analgesics. Therefore, they as antagonists have the potential to counteract the harmful effects of opioids on the gut mucosa, bacterial translocation and inflammation despite the high levels of exogenous opioids present in patients with pancreatitis. PAMORAs do not cross the blood-brain barrier and consequently do not interfere with analgesia or other central effects of opioids. We hypothesize that treatment with the PAMORA methylnaltrexone will antagonize the harmful effects of opioids without reducing analgesia in patients with AP and hence reduce disease severity and improve clinical outcomes. If successful, this sub-study will for the first time document the effects of a targeted pharmacotherapy in AP with the potential benefit of improved patient outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04743570
Study type	Interventional
Source	Aalborg University Hospital
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	May 14, 2021
Completion date	April 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05410795` - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting	`NCT04195347` - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase	Phase 1/Phase 2
Completed	`NCT04735055` - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed	`NCT02928718` - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated	`NCT02885441` - Treatment of Acute Pancreatitis With Ketorolac	Phase 4
Completed	`NCT02563080` - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting	`NCT01626911` - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis	N/A
Completed	`NCT01507766` - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis	Phase 4
Completed	`NCT04901949` - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting	`NCT04814693` - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis	N/A
Completed	`NCT02743364` - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis	Phase 2
Recruiting	`NCT05281458` - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections	N/A
Not yet recruiting	`NCT04990336` - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis	N/A
Not yet recruiting	`NCT03259880` - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals	N/A
Completed	`NCT02543658` - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension	Phase 2
Recruiting	`NCT06023771` - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting	`NCT05501314` - Remote Home Monitoring Acute Pancreatitis	N/A
Completed	`NCT02897206` - Imipenem Prophylaxis in Patients With Acute Pancreatitis	Phase 4
Recruiting	`NCT03634787` - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting	`NCT04989166` - Effect of Nano-curcumin Supplementation in Acute Pancreatitis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms